These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33657639)

  • 1. The less-known face of dupilumab: its role in mesenchymal stem cells by interleukin-13 modulation.
    Campanati A; Di Vincenzo M; Radi G; Rizzetto G; Carnevale G; Marchi S; Orciani M; Offidani A
    Br J Dermatol; 2021 Jul; 185(1):217-219. PubMed ID: 33657639
    [No Abstract]   [Full Text] [Related]  

  • 2. Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history.
    Corren J; Castro M; Ford LB; Bernstein JA; Jayawardena S; Maroni J; Rowe P; Amin N; Pirozzi G; Graham NMH; Khan A; Eckert L; Teper A
    Ann Allergy Asthma Immunol; 2019 Aug; 123(2):222-224.e1. PubMed ID: 31075309
    [No Abstract]   [Full Text] [Related]  

  • 3. Dupilumab for the treatment of asthma.
    Santini G; Mores N; Malerba M; Mondino C; Anzivino R; Macis G; Montuschi P
    Expert Opin Investig Drugs; 2017 Mar; 26(3):357-366. PubMed ID: 28085503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia.
    Tanabe N; Matsumoto H; Hamada S; Ito I; Hirai T
    Allergol Int; 2021 Apr; 70(2):274-276. PubMed ID: 33208274
    [No Abstract]   [Full Text] [Related]  

  • 6. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
    Castro M; Corren J; Pavord ID; Maspero J; Wenzel S; Rabe KF; Busse WW; Ford L; Sher L; FitzGerald JM; Katelaris C; Tohda Y; Zhang B; Staudinger H; Pirozzi G; Amin N; Ruddy M; Akinlade B; Khan A; Chao J; Martincova R; Graham NMH; Hamilton JD; Swanson BN; Stahl N; Yancopoulos GD; Teper A
    N Engl J Med; 2018 Jun; 378(26):2486-2496. PubMed ID: 29782217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab (Dupixent) for Asthma.
    Barry K; Gorelik D
    Am Fam Physician; 2020 Feb; 101(4):244-245. PubMed ID: 32053330
    [No Abstract]   [Full Text] [Related]  

  • 8. [Innovations in the treatment of severe asthma].
    Buss G; Spertini F
    Rev Med Suisse; 2017 Jan; 13(544-545):18-19. PubMed ID: 28703528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalisation of MRI ventilation heterogeneity in severe asthma by dupilumab.
    Svenningsen S; Haider EA; Eddy RL; Parraga G; Nair P
    Thorax; 2019 Nov; 74(11):1087-1088. PubMed ID: 31285363
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of refractory asthma with antibodies].
    Lommatzsch M
    Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asthma Yardstick Update: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma.
    Oppenheimer JJ; Borish L
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):660-661. PubMed ID: 30172715
    [No Abstract]   [Full Text] [Related]  

  • 12. Dupilumab: A Review in Moderate to Severe Asthma.
    Deeks ED
    Drugs; 2019 Nov; 79(17):1885-1895. PubMed ID: 31728838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab for prurigo nodularis: Case series and review of the literature.
    Holm JG; Agner T; Sand C; Thomsen SF
    Dermatol Ther; 2020 Mar; 33(2):e13222. PubMed ID: 31917498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular surface disease associated with dupilumab treatment for atopic diseases.
    Utine CA; Li G; Asbell P; Pflugfelder S; Akpek E
    Ocul Surf; 2021 Jan; 19():151-156. PubMed ID: 32439390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review.
    Ando K; Tanaka A; Sagara H
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab cuts both ways.
    Heymann WR
    J Am Acad Dermatol; 2020 Jul; 83(1):35-36. PubMed ID: 32437719
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic potential of the interleukin-4/interleukin-13 inhibitor dupilumab for treating IgG4-related disease.
    Nakajima I; Taniguchi Y; Tsuji H; Mizobuchi T; Fukuda K
    Rheumatology (Oxford); 2022 May; 61(6):e151-e153. PubMed ID: 34962989
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab: Basic aspects and applications to allergic diseases.
    Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
    Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics.
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Clin Exp Allergy; 2020 Apr; 50(4):442-452. PubMed ID: 31943429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 4 and interleukin 13 inhibition: A promising therapeutic approach in bullous pemphigoid.
    Geller S
    J Am Acad Dermatol; 2020 Jul; 83(1):37-38. PubMed ID: 32179081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.